Skip to content

Annexon ANNX Total Liabilities

Total Liabilities at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$9.45B+15.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$45.57M+128%
Vor Biopharma logo
Vor BiopharmaVOR
$657.17M+1,420%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$36.81M+32.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$187.06M-22.9%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$20.44M+12.0%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Reported directly by Annexon in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's total liabilities?
Annexon (ANNX) reported total liabilities of $58.36M in Q1 2026.
How has Annexon's total liabilities changed year-over-year?
Annexon's total liabilities decreased by 1.5% year-over-year, from $59.24M to $58.36M.
What is the long-term trend for Annexon's total liabilities?
Over 5 years (2020 to 2025), Annexon's total liabilities has grown at a 41.4% compound annual growth rate (CAGR), from $11.67M to $65.92M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.